Description
Rosuvastatin 10mg+Ezetimibe 10mg
Used For High Risk Dyslipidemic Patients
Dual mechanism & synergistic LDL-C reduction greater than either agent alone.
Dosage:Available in oral tablet form. Once Daily
RDL EZ
Used For High Risk Dyslipidemic Patients
Rosuvastatin: Inhibits HMG-CoA reductase, blocking endogenous cholesterol synthesis in the liver.
Ezetimibe: Inhibits NPC1L1 transporter in the intestine, reducing dietary & biliary cholesterol absorption.
